卖什么
We make unmakeable proteins with radical advanced biomanufacturing.
商业模式拆解
买家：谁掌握预算？
未核实R&D and manufacturing/BD leads at diagnostics (IVD), biopharma and crop protection companies.
触发点：什么让他们现在购买？
Proteins that traditional systems cannot express, or need at gram scale for regulatory dossiers and IVD commercial production.
工作流：什么输入变成什么输出？
Milestones: strain generation, expression optimization, process development, then production and characterization at gram scale (one case study reports sequence to scale in seven months).
经济账：省了什么，怎么收费？
Custom contract manufacturing/development per project; 6,000 sq ft Instar 1.0 biofactory, claims 30x output of conventional protein technology.
渠道：怎么接触到客户？
Consultative sales: "Request a Protein Consult"; case studies and newsroom.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2020 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.